Desvenlafaxine Tablet, Extended Release
NDC Package 10135-821-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Desvenlafaxine tablets is desvenlafaxine is used to treat depression. This formulation utilizes a tablet, extended release delivery system. Marketed by Marlex Pharmaceuticals, Inc., this product is identified by NDC 10135-821 and is authorized under FDA application ANDA204805.

Identification & Billing

NDC Package Code
10135-821-10
Package Description
1000 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
10135-821
11-Digit Billing Format
10135082110
RxNorm Crosswalk
  • RxCUI: 1874553 - desvenlafaxine succinate 100 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1874553 - 24 HR desvenlafaxine succinate 100 MG Extended Release Oral Tablet
  • RxCUI: 1874553 - desvenlafaxine 100 MG (as desvenlafaxine succinate 152 MG) 24HR Extended Release Oral Tablet
  • RxCUI: 1874559 - desvenlafaxine succinate 50 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1874559 - 24 HR desvenlafaxine succinate 50 MG Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Desvenlafaxine
Non-Proprietary Name
Desvenlafaxine
Substance Name
Desvenlafaxine Succinate
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DESVENLAFAXINE SUCCINATE 50 mg/1
Pharmacologic Class
Usage Information
Desvenlafaxine is used to treat depression. It may improve your mood, feelings of well-being, and energy level. Desvenlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Regulatory & Marketing

Labeler Name
Marlex Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA204805
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-01-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (10135-821). Click a package code to view its specific billing and regulatory data.

10135-821-14
14 TABLET, EXTENDED RELEASE in 1 BOTTLE
10135-821-30
30 TABLET, EXTENDED RELEASE in 1 BOTTLE
10135-821-90
90 TABLET, EXTENDED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10135-821-10 identifies a specific commercial package of 1000 tablet, extended release in 1 bottle of Desvenlafaxine, a human prescription drug labeled by Marlex Pharmaceuticals, Inc.. This tablet, extended release is formulated for oral use and contains desvenlafaxine succinate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Marlex Pharmaceuticals, Inc. on July 01, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Desvenlafaxine is used to treat depression. It may improve your mood, feelings of well-being, and energy level. Desvenlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

How is this Marlex Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10135082110. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
10135-821-10
11-Digit CMS (5-4-2)
10135-0821-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.